Inactive Instrument

Proteostasis Therapeutics, Inc. Stock price

Equities

PTI

US74373B1098

Dynamic Chart
Proteostasis Therapeutics, Inc.(NasdaqGM:PTI) dropped from NASDAQ Composite Index CI
Yumanity Therapeutics Inc. completed the acquisition of Proteostasis Therapeutics, Inc. in a reverse merger transaction. CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Proteostasis Therapeutics, Inc. Announces Resignation of Sheila Wilson as Chief Operating Officer CI
Proteostasis Therapeutics : Biotech Startup Yumanity Sets Reverse Merger With Proteostasis DJ
Transcript : Proteostasis Therapeutics, Inc., Yumanity Therapeutics Inc. - M&A Call
Yumanity Therapeutics Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire Proteostasis Therapeutics, Inc. for approximately $150 million in a reverse merger transaction. CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Proteostasis Therapeutics, Inc.(NasdaqGM:PTI) added to Russell Microcap Growth Index CI
Wall Street closes higher as recovery signs soothe protest, pandemic worries RE
Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19 CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Proteostasis Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Proteostasis Therapeutics, Inc. Announces New Publication on the Mechanism of Action of a Novel Class of CFTR Modulators Called Amplifiers in the Journal of Cystic Fibrosis CI
Proteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic Fibrosis CI
More news
Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company's pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Proteostasis Therapeutics, Inc. - Nasdaq